Navigation Links
Medivation Announces Senior Management Promotions
Date:3/25/2008

SAN FRANCISCO, March 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the promotions of Michele D. Bronson, Ph.D., to vice president, regulatory and quality, Mohammad Hirmand, M.D., to vice president, clinical development, and Joyce Mordenti, Ph.D., to vice president, translational medicine.

"As we enter Phase 3 development for our lead product candidate, we are strengthening the team to lead and advance our clinical programs," said Lynn Seely, M.D., chief medical officer of Medivation. "Drs. Bronson, Hirmand and Mordenti's knowledge of the clinical trial and regulatory process will be invaluable as we move Dimebon forward in Alzheimer's and Huntington's diseases and complete our Phase 1-2 MDV3100 clinical trial in hormone-refractory prostate cancer. We look forward to their continued productivity and leadership."

Dr. Bronson joined Medivation in September 2006 as senior director, regulatory, quality and project management. She led the Company's end-of-Phase 2 meeting with the U.S. Food and Drug Administration for Dimebon(TM). Based on those discussions, Medivation plans to begin a pivotal confirmatory Phase 3 trial of Dimebon in mild-to-moderate Alzheimer's disease in the second quarter of 2008. Prior to joining Medivation, Dr. Bronson held positions of increasing responsibility in regulatory affairs at Chiron Corporation, including director in the oncology development organization, where she was responsible for approved products and developmental therapeutics. She joined Chiron Corporation from SEQUUS Pharmaceuticals where she was responsible for the development and accelerated approval of DOXIL for the treatment of ovarian cancer. Dr. Bronson began her career in drug development at Cato Researc
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
2. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Neurostimulation - A Global Market Perspective ,, http://www.reportlinker.com/p01642
Breaking Biology Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6
...ivoSciences LLC , a startup biotechnology firm wit...ug developers bridge the gap between molecular and...heart diseases, skin disorders, and other maladies...rovide that bridge. , ,Using tissues derived from ...meeting of the Wisconsin Biotechnology and Medica...
...onsin can create a dynamic, creative economy in it...hedding its "welfare state" mentality, the leader ... executives. , ,John Jazwiec, who earlier this yea...siness climate, outlined what he acknowledged were...ast of the Independent Business Association of Wi...
...of identity theft (IDT), yet unless you have been ...h risk. An alarming figure is that over half of th...lace of business, employer, or other entity (not-f... , ,All entities and certain individuals are requi...plement measures, policies, procedures, and employ...
Other Biology Technology:Biotech firm uses live heart tissue in drug screens 2Biotech firm uses live heart tissue in drug screens 3RedPrairie exec calls for 50 percent tax cut 2RedPrairie exec calls for 50 percent tax cut 3RedPrairie exec calls for 50 percent tax cut 4Identity theft: The business time bomb 2Identity theft: The business time bomb 3Identity theft: The business time bomb 4
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)Contents of this message: , , Preliminary Press Conference Topics, Last Call! Press Field Trip to California Academy of Sciences museum, Attention PIOs: Sending Press Releases to Fall meeting, N
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
Breaking Biology News(10 mins):Lifelong memories linked to stable nerve connections 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 1Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 2Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 3Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 4Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 5Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 6Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 7Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 8Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis C Virus 28HCV 29 48416 9Patients Say Costs Determining Factor in Their Treatment Decisions 48414 1Patients Say Costs Determining Factor in Their Treatment Decisions 48414 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 1AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 2AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 3AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 4AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia 12555 5
...who studied a man-made wetland in Ohio for two yea... cleaned water as well as or better than would a n...n agricultural area, reduced levels of phosphorus ...hosphorus and nitrates are prime ingredients in bo...ls of these nutrients can cause algae to flourish,...
...alth Organization (WHO) and the United Nations Chi...es are on target to halve deaths from measles, a l...his year. Global measles deaths have plummeted by ...in 2003. , The largest reduction occurred in Afri...ase, where estimated measles deaths decreased by 4...
...at the McGill University Health Centre (MUHC), in ...cer. In a new study, published in the on-line edit...eek, the researchers document a reduction in the g...hibition of the gene. , The new target gene is cal... Researchers were able to inhibit the function of ...
Other Biology News:Man-made wetland's effectiveness similar to natural marsh 2Man-made wetland's effectiveness similar to natural marsh 3Measles Deaths Worldwide Drop By Nearly 40% Over Five Years 2
Anti-JIP 1 / 2 (SH3) Polyclonal Antibody, Unconjugated, Clone ZMD.177 from Invitrogen
Rabbit Anti-oligophrenin-1 Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Anti-Rat WAVE 1 Monoclonal Antibody, Unconjugated, Clone 1.T.4 from Abcam
Goat Anti-KV beta.1 (Q-13) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: